Replies to post #43838 on Cytodyn Inc (CYDY)

[Amatuer17]

Look at inconstancy in PR

“therapeutic indications, today announced the completion of development of the Receptor Occupancy Test to measure the expression of CCR5 in HIV and tumor cells that are occupied by leronlimab. Development of this test could more precisely guide CytoDyn in identification of patients at screening for monotherapy. “

The title says - finalizes development’ and body of message says completion of development - what is correc? Is the test ready to be used?

Also - will test determine CCR5 occupancy of HIV and tumor cells (which will be useful pre- treatment for dose determination) OR CCR5 expression in HIV and tumor cells that are occupied by Lero (which will have to be post treatment and may measure possible effectivity)

Seems this test is unique - no one else is carrying it - so why not say that?

Why he repeated same stuff about pro-140 again?

When is the fda meeting? Sept-Oct? You are looking at 1st dosing in Dec or Q1-2020